文献速递消化系统肿瘤

转移性结直肠癌二线后治疗:系统综述

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
PubMed 文献 · Ann Oncol · 2018-01-01

该系统综述检索2002年1月至2017年5月文献,评估转移性结直肠癌二线后单药或联合治疗的疗效、安全性和患者报告结局,共纳入68项研究进行定性合成。有限证据支持化疗或靶向治疗再挑战;与安慰剂相比,三氟胸苷/替匹嘧啶(TAS-102)或瑞戈非尼显示总生存获益,两者疗效无差异。结论支持在二线治疗失败后先使用获批药物再考虑再挑战。

要点

  • 二线后有限证据支持化疗或靶向再挑战。
  • TAS-102或瑞戈非尼较安慰剂有总生存获益。
  • TAS-102与瑞戈非尼疗效未见差异。

核心结论

  • 二线治疗失败的mCRC患者应在再挑战前使用TAS-102或瑞戈非尼等获批药物。

研究设计与样本

  • 系统综述检索Cochrane、EMBASE、Medline(2002年1月至2017年5月)及癌症会议数据库(2014年1月至2017年6月),最终纳入68项研究进行定性合成。

主要发现

  • 支持化疗、靶向治疗或两者再挑战的证据有限。
  • 与安慰剂相比,TAS-102或瑞戈非尼在既往接受常规化疗和靶向治疗的患者中显示总生存获益。
  • 未发现证据提示TAS-102与瑞戈非尼之间存在疗效差异。

关键数值与推荐

  • 与安慰剂相比,TAS-102或瑞戈非尼显示总生存获益。
  • 未发现TAS-102与瑞戈非尼疗效差异的证据。

临床怎么用

  • 二线治疗失败后优先选用TAS-102或瑞戈非尼,再考虑再挑战。
  • 选择治疗时应考虑患者意愿和生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal chemotherapeutic regimen for use beyond the second line for patients with metastatic colorectal cancer (mCRC) remains unclear. MATERIALS AND METHODS: We systematically searched the Cochrane Database of Systematic Reviews, EMBASE and Medline for records published between January 2002 and May 2017, and cancer congress databases for records published between January 2014 and June 2017. Eligible studies evaluated the efficacy, safety and patient-reported outcomes of monotherapies or combination therapies at any dose and number of treatment cycles for use beyond the second line in patients with mCRC. Studies were assessed for design and quality, and a qualitative data synthesis was conducted to understand the impact of treatment on overall survival and other relevant cancer-related outcomes. RESULTS: The search yielded 938 references of which 68 were included for qualitative synthesis. There was limited evidence to support rechallenge with chemotherapy, targeted therapy or both. Compared with placebo, an overall survival benefit for trifluridine/tipiracil (also known as TAS-102) or regorafenib has been shown for patients previously treated with conventional chemotherapy and targeted therapy. There was no evidence to suggest a difference in efficacy between these treatments. Patient choice and quality of life at this stage of treatment should also be considered when choosing an appropriate therapy. CONCLUSIONS: These findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second line before any rechallenge in patients with mCRC who have failed second-line treatment.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018. PMID: 29452346. doi:10.1093/annonc/mdy038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。